(isatuximab) Phase 3 trial met primary endpoint of progression free survival in patie | IMGN Message Board Posts


IMGN   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  57277 of 57658  at  12/7/2023 2:26:30 PM  by

GaryM


 In response to msg 57274 by  very
view thread

Re: (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patie

Does anyone know what IMGN's remaining financial interest is in this drug.  I know that they've monetized products, but believe that we may still be entitled to both milestone payments and royalties on sales of this, which ABBV would inherit if the buyout goes through as stated.
 
Does anyone think that SNY could be the one to put in a counter offer?  My favorites for such an offer would include them, Roche, Amgen, etc. because of partnerships they've had with IMGN for decades. 
 
Is anyone else buying out of the money calls?  I'll take a small loss if we don't get an offer, but the gain could be huge if we do.  I certainly hope that no shareholder vote will come before an Annual Report is issued and investors, especially the Institutions, can truly evaluate what the company ought to be worth.
 
Gary 
 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 0  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board




Financial Market Data provided by
.
Loading...